safetyriskБезопасность и риск фармакотерапииSafety and Risk of Pharmacotherapy2312-78212619-1164Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)safetyrisk-10Research ArticleОБЗОРЫ И ОРИГИНАЛЬНЫЕ СТАТЬИREVIEWS AND ORIGINAL ARTICLESНЕЖЕЛАТЕЛЬНЫЕ ЯВЛЕНИЯ ИНТЕРФЕРОНОВ СИСТЕМНОГО ДЕЙСТВИЯADVERSE EVENTS OF INTERFERONS WITH SYSTEMIC EFFECTТопоровАлександр АндреевичToporovA. A.noemail@neicon.ruКолбинАлексей СергеевичKolbinA. S.alex.kolbin@mail.ruПервый Санкт-Петербургский государственный медицинский университет имени академика И.П. ПавловаРоссияPavlov First Saint Petersburg State Medical UniversityRussian FederationПервый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова; Санкт-Петербургский государственный университетРоссияPavlov First Saint Petersburg State Medical University; Saint Petersburg State UniversityRussian Federation20152002201802511Copyright © Топоров А.А., Колбин А.С., 20182018Топоров А.А., Колбин А.С.Toporov A.A., Kolbin A.S.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.risksafety.ru/jour/article/view/10

Проведен систематический обзор данных за период с 2000 г. по 2014 г., полученных при изучении нежелательных явлений, развившихся при использовании интерферонов системного действия. Методология работы основана на поиске публикаций, представленных в международных базах данных. Применялись критерии включения и исключения. Для проведения анализа отобраны исследования, в которых были описаны нежелательные явления интерферонов системного действия. Установлено, что интерфероны способны вызывать многочисленные нежелательные явления: гриппоподобный синдром (55%), депрессия (30%), нейтропения (20%), анемия (13%) и другие. Система фармаконадзора может прогнозировать и своевременно выявлять данные нежелательные явления, так как все они являются предсказуемыми.

Objective: To explore the profile of adverse events associated with interferon therapy. Design: Systematic review. Data sources: Electronic and paper records in subject area from 2000 to 2014. Methods: We searched for the studies on safety and tolerability containing adverse events of interferons with systemic effect. Results: The most frequent adverse events were: flu-like syndrome (55%), depression (30%), neutropenia (20%), anemia (13%). Conclusion: Adverse events are a very serious problem of interferon treatment. System of pharmacovigilance provides forecasting and early identification of these adverse events, as they are predictable.

нежелательные явленияинтерфероныфармаконадзорadverse eventpharmacovigilanceinterferonside effectReferencesFried M. Side effects of therapy of hepatitis C and their management. Hepatology. 2002; 36(5): 237-44.Fried M. Side effects of therapy of hepatitis C and their management. Hepatology. 2002; 36(5): 237-44.Chevaliez S., Pawlotsky J.M. Interferons and their use in persistent viral infections. Handb Exp Pharmacol. 2009; (189): 203-41.Chevaliez S., Pawlotsky J.M. Interferons and their use in persistent viral infections. Handb Exp Pharmacol. 2009; (189): 203-41.Gaeta G., Precone D., Felaco F. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in ‘real world’ patients with chronic hepatitis C. Alimentary Pharmacology & Therapeutics. 2002; 16(9): 1633-1639.Gaeta G., Precone D., Felaco F. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in ‘real world’ patients with chronic hepatitis C. Alimentary Pharmacology & Therapeutics. 2002; 16(9): 1633-1639.Witthöft T., Мüller K., Wiedmann K. Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronichepatitis C in clinical practice: the german open safety trial. J Viral Hepat. 2007; 14(11): 788-796.Witthöft T., Мüller K., Wiedmann K. Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronichepatitis C in clinical practice: the german open safety trial. J Viral Hepat. 2007; 14(11): 788-796.Middleton M., Hauschild A., Thomson D. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-a2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. Ann. Oncol. 2007; 18(10): 1691-1697.Middleton M., Hauschild A., Thomson D. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-a2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. Ann. Oncol. 2007; 18(10): 1691-1697.Anil J., Anjum J., Saad K. Tropical Gastroenterology. 2009; 30(3): 175-176.Anil J., Anjum J., Saad K. Tropical Gastroenterology. 2009; 30(3): 175-176.Anil J., Saad K., Emadi S. et al. Polymyositis during pegylated alpha interferon ribavirin therapy in chronic hepatitis. Indian J Gastroenterol. 2007; 26: 147-8.Anil J., Saad K., Emadi S. et al. Polymyositis during pegylated alpha interferon ribavirin therapy in chronic hepatitis. Indian J Gastroenterol. 2007; 26: 147-8.Cirigliano G., Rossa A., Tavoni A. Polymyositis occurring during alpha interferon treatment for malignant melanoma-a case report. Rheumatol Int. 1999; 19: 65-7.Cirigliano G., Rossa A., Tavoni A. Polymyositis occurring during alpha interferon treatment for malignant melanoma-a case report. Rheumatol Int. 1999; 19: 65-7.Dietrich L., Bridges A., Albertini M. Dermatomyositis after interferon alpha treatment. Med Oncol. 2000; 14; 64-9.Dietrich L., Bridges A., Albertini M. Dermatomyositis after interferon alpha treatment. Med Oncol. 2000; 14; 64-9.Максимов В.А. Виферон против HCV. Опыт использования. / В.А. Максимов; В.А. Неронов; С.Н. Зеленцов; С.Д. Карабаев // Эффективная фармакотерапия. 2010 - № 1(12) - с. 10-15.Максимов В.А. Виферон против HCV. Опыт использования. / В.А. Максимов; В.А. Неронов; С.Н. Зеленцов; С.Д. Карабаев // Эффективная фармакотерапия. 2010 - № 1(12) - с. 10-15.Serra D., Sun H., Karwowska S. Single-Dose Pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers. Antimicrob Agents Chemother. 2011; 55(2): 473-477.Serra D., Sun H., Karwowska S. Single-Dose Pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers. Antimicrob Agents Chemother. 2011; 55(2): 473-477.Bhattacharya D., Umbleja T., Carrat F. Women Experience Higher Rates of Adverse Events During HCV Therapy in HIV Infection: A Meta-Analysis. J Acquir Immune Defic Syndr. 2011; 55(2): 170-175.Bhattacharya D., Umbleja T., Carrat F. Women Experience Higher Rates of Adverse Events During HCV Therapy in HIV Infection: A Meta-Analysis. J Acquir Immune Defic Syndr. 2011; 55(2): 170-175.Еналеева Д.Ш. Сравнительная характеристика нежелательных явлений на противовирусную терапию у пациентов с хроническим гепатитом С. / Д.Ш. Еналеева; Э.Р. Манапова; С.В. Ткачева; Ю.В. Фазылова // Практическая медицина. 2012 - № 1(12). с. 2-23.Еналеева Д.Ш. Сравнительная характеристика нежелательных явлений на противовирусную терапию у пациентов с хроническим гепатитом С. / Д.Ш. Еналеева; Э.Р. Манапова; С.В. Ткачева; Ю.В. Фазылова // Практическая медицина. 2012 - № 1(12). с. 2-23.Markowitz C., Patel P., Boateng F. Combined effect of nursing support and adverse event mitigation on adherence to interferon beta-1b therapy in early multiple sclerosis. J MS Care. 2012; 14(4): 198-208.Markowitz C., Patel P., Boateng F. Combined effect of nursing support and adverse event mitigation on adherence to interferon beta-1b therapy in early multiple sclerosis. J MS Care. 2012; 14(4): 198-208.Freedman M. Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis. Expert Opin Biol Ther. 2014; 14: 1207-1214.Freedman M. Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis. Expert Opin Biol Ther. 2014; 14: 1207-1214.Comi G., Filippi M., Barkhof F. et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet. 2001; 357: 1576-82.Comi G., Filippi M., Barkhof F. et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet. 2001; 357: 1576-82.Sapra S., Chang E., Broder M. et al. Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study. BMC Health Services Research. 2014; 14: 429.Sapra S., Chang E., Broder M. et al. Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study. BMC Health Services Research. 2014; 14: 429.Wang K., Xing H., Zhao H. et al. Efficacy and tolerability of low-dose interferon-a in hemodialysis patients with chronic hepatitis C virus infection. WJG. 2014; 20(14): 4071-4075.Wang K., Xing H., Zhao H. et al. Efficacy and tolerability of low-dose interferon-a in hemodialysis patients with chronic hepatitis C virus infection. WJG. 2014; 20(14): 4071-4075.Manceau P., Latarche C., Pittion S. et al. Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis. BMC Neurology. 2014; 14: 215.Manceau P., Latarche C., Pittion S. et al. Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis. BMC Neurology. 2014; 14: 215.Schellekens H., Casadevall N. Neutralizing antibodies falling on treatment of multiple sclerosis with interferon beta-1b: experience falling on the first three years. Neurology. 1996; 47(4): 889-894.Schellekens H., Casadevall N. Neutralizing antibodies falling on treatment of multiple sclerosis with interferon beta-1b: experience falling on the first three years. Neurology. 1996; 47(4): 889-894.Sorensen P., Ross C., Clemmesen K. Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362 (9391): 1184-1191.Sorensen P., Ross C., Clemmesen K. Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362 (9391): 1184-1191.Malucchi S., Sala A., Gilli F. Neutralizing antibodies reduce the efficacy of IFN beta during treatment of multiple sclerosis. Neurology 2004; 62(11): 2031-2037.Malucchi S., Sala A., Gilli F. Neutralizing antibodies reduce the efficacy of IFN beta during treatment of multiple sclerosis. Neurology 2004; 62(11): 2031-2037.Sato D., Nakashima I., Fukazawa T. Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients. Tokohu J Exp Med. 2012; 228(2): 85-92.Sato D., Nakashima I., Fukazawa T. Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients. Tokohu J Exp Med. 2012; 228(2): 85-92.Clemens M.J. Interferons and apoptosis. J Interferon Cytokine Res. 2003; 23: 277-292.Clemens M.J. Interferons and apoptosis. J Interferon Cytokine Res. 2003; 23: 277-292.Pedersen I.M., Cheng G., Wieland S. et al. Interferon modulation of cellular microRNA as an antiviral mechanism. Nature. 2007; 499: 919-922.Pedersen I.M., Cheng G., Wieland S. et al. Interferon modulation of cellular microRNA as an antiviral mechanism. Nature. 2007; 499: 919-922.Guidotti L.G., Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001; 19: 65-91.Guidotti L.G., Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001; 19: 65-91.Pichler W.J. Adverse side-effects to biological agents. Allergy. 2006; 61(8): 912-20.Pichler W.J. Adverse side-effects to biological agents. Allergy. 2006; 61(8): 912-20.

The authors declare that there are no conflicts of interest present.